{
  "name" : "dacemirror.sci-hub.se_journal-article_75dd91552bde9e985d7cada27dfea1a0_rachamalla2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Efficient anti-tumor nano-lipoplexes with unsaturated or saturated lipid induce differential genotoxic effects in mice",
    "authors" : [ "Hari Krishnareddy Rachamalla", "Sujan Kumar Mondal", "Shruti S. Deshpande", "Kathyayani Sridharan", "Kalpana Javaji", "Madan Mohan Chandra Sekhar", "Madan Mohan Chandra", "Sekhar Jaggarapu", "Sudhakar Jinka", "Vishnusravan Bollu", "Sunil Misra", "Rajkumar Banerjee" ],
    "emails" : [ "banerjee@iict.res.in", "smisra@iict.res.in" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=inan20\nNanotoxicology\nISSN: 1743-5390 (Print) 1743-5404 (Online) Journal homepage: https://www.tandfonline.com/loi/inan20\nEfficient anti-tumor nano-lipoplexes with unsaturated or saturated lipid induce differential genotoxic effects in mice\nHari Krishnareddy Rachamalla, Sujan Kumar Mondal, Shruti S. Deshpande, Kathyayani Sridharan, Kalpana Javaji, Madan Mohan Chandra Sekhar Jaggarapu, Sudhakar Jinka, Vishnusravan Bollu, Sunil Misra & Rajkumar Banerjee\nTo cite this article: Hari Krishnareddy Rachamalla, Sujan Kumar Mondal, Shruti S. Deshpande, Kathyayani Sridharan, Kalpana Javaji, Madan Mohan Chandra Sekhar Jaggarapu, Sudhakar Jinka, Vishnusravan Bollu, Sunil Misra & Rajkumar Banerjee (2019): Efficient anti-tumor nano-lipoplexes with unsaturated or saturated lipid induce differential genotoxic effects in mice, Nanotoxicology, DOI: 10.1080/17435390.2019.1643049 To link to this article: https://doi.org/10.1080/17435390.2019.1643049\nAccepted author version posted online: 11 Jul 2019.\nSubmit your article to this journal\nArticle views: 8\nView Crossmark data\nEfficient anti-tumor nano-lipoplexes with unsaturated or saturated lipid induce differential genotoxic effects in mice\nHari Krishnareddy Rachamalla # , Sujan Kumar Mondal # , Shruti S. Deshpande, Kathyayani Sridharan, Kalpana Javaji, Madan Mohan Chandra Sekhar Jaggarapu, Sudhakar Jinka, Vishnusravan Bollu, Sunil Misra*, Rajkumar Banerjee*"
    }, {
      "heading" : "Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road,",
      "text" : "Hyderabad 500007, Telangana, India &Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad-201 002, Uttar Pradesh, India.\nCorrespondence to:\nDr. Rajkumar Banerjee, Applied Biology Division, CSIR – Indian Institute of Chemical Technology (CSIR-IICT), Uppal Road, Tarnaka, Hyderabad 500 007, Telangana State, India. Tel: +91 4027191859. E-mail: banerjee@iict.res.in\nDr. Sunil Misra, Applied Biology Division, CSIR – Indian Institute of Chemical Technology (CSIR-IICT), Uppal Road, Tarnaka, Hyderabad 500 007, Telangana State, India. Tel: +91 4027191379. E-mail: smisra@iict.res.in\n# Equal contribution\nAc ce\npt ed\nM an\nus cr\nipt"
    }, {
      "heading" : "Abstract",
      "text" : "Cationic lipids are well known excipients for nanometric liposomal gene delivery systems. However, because of the suspected, collateral toxicity in normal cells, the use of cationic lipids for the treatment of human tumor is largely limited. Recently, using a glucocorticoid receptor (GR)-targeted liposomal, anticancer delivery system (DXE nano-lipoplex), which carried cationic lipid of saturated twin aliphatic chains, we accomplished efficient anti-tumor effect in aggressive and drug-resistant tumor models of breast cancer stem cells, melanoma and pancreatic cancer. However, to explore its human clinical use, a complete in vivo genotoxicological profilebased safety assessment was due. In addition, in this study we incorporated another nanolipoplex (D1XE) that carried cationic lipid with one unsaturated aliphatic chain. The study was to compare the genotoxic and anti-tumor profile of both the lipoplexes, which differ by the chemical identity of only one constituent cationic lipid, i.e., lipid either carrying both the saturated aliphatic chains or carrying one saturated and one unsaturated aliphatic chains. It is well-known that unsaturated aliphatic chains in lipid impart efficient cell surface fusogenic property in lipid formulations. Herein, we report that nanoplex with unsaturated cationic lipid (D1XE) exhibited better physical appearance with less flocculent behavior than nanoplex with saturated lipid (DXE). Upon multiple injections, D1XE nanoplex imparted better tumor regression but most importantly, exhibited much lower overall toxicity (e.g., genotoxicity, weight loss etc.) than DXE nanoplex. With higher antitumor effect but lower genotoxic effect, D1XE is proved to be a better nanoplex than DXE for potential clinical trial. Thus, this study clearly delineates the importance of incorporating a constituent lipid that carries single unsaturated aliphatic chain towards developing efficient anti-tumor nano-lipoplexes with reduced genotoxicity."
    }, {
      "heading" : "Keywords",
      "text" : "Cationic liposome, unsaturated lipid, glucocorticoid receptor, mammalian cells, cytotoxicity, melanoma model, swiss albino mice, genotoxicity, risk assessment.\nAc ce\npt ed\nM a\nus cr\nipt"
    }, {
      "heading" : "Introduction",
      "text" : "Evaluation of acute or chronic, genotoxicological profiling is necessary for projecting\nclinical success of any nano-formulations (Alexander et al. 2017, AshaRani et al. 2009, Conde et al. 2014, Lee et al. 2005, Xie et al. 2011). There are multiple nano-formulations of different physical and chemical features carrying bioactive molecules for the treatment of tumor, which are either approved for treatment of human cancers or are in clinical trials (Anselmo and Mitragotri 2016, Bulbake et al. 2017). Among cationic liposome-based anticancer therapeutics, there are few which are in market or in advanced phases of clinical trials (Anselmo and Mitragotri 2016, Vasievich et al. 2011). Cationic lipids, owing to their positive surface charges, make efficient electrostatic interaction with cell surfaces, which are negatively charged in nature. However, their clinical potential say, as anticancer therapeutics is limited for their suspected non-specific and off-target effects on non-cancer cells. The efficient clinical utility of cationic liposomes can be attained by selectively engineering the structure of cationic lipids, varying molecular architecture of lipids such as chain length and nature, polar head and linker, etc. that determines fusogenicity and delivery of drug and nucleic acid cargoes (Marepally et al. 2011, Zylberberg et al. 2017). Cationic lipids chosen for an effective drug/gene delivery system must show high stability, high penetration efficiency, high cargo release but certainly very low toxicity (Zylberberg et al. 2017). However, to our knowledge no systemic data with comparative toxicological profiles of lipid-based drug/gene nano-delivery systems especially with respect to the presence of saturated/unsaturated aliphatic chains are available. Receptor-targeted liposomal drug/gene delivery systems offer a promising platform compared to passively targeted liposomal nanoformulations owing to their efficient targeting ability and specificity (Rosenblum et al. 2018). These strategies involve modification of cationic liposomes with target-specific ligands (either as a modified lipid or as a co-lipid) to enhance intracellular uptake, transfection efficiency, targeted drug release, and reduce off-target effects (Deshpande et al. 2013). Previously, we developed a novel glucocorticoid receptor (GR)-targeted cationic liposome-based nanoformulation (DXE). It contains, among other co-lipids and ingredients, a cationic lipid bearing two saturated, aliphatic hydrocarbon chains (called, DODEAC or D0). Upon electrostatic complexation with anticancer plasmid, anti-miR-Hsp90 plasmid (Pore et al. 2013), the formulation assumed a thick and flocculent nano-lipoplex. On multiple injections, in one hand, it resulted in efficient growth retardation in aggressive forms of various orthotopic tumors in mice (Ahmad et al. 2016, Mondal et al. 2016), but in other hand, induced weakness and loss of weight. We speculated that these unwanted toxic effects were because of lipoplex’s indefinite tendency to precipitate out, resulting in non-uniform bio-distribution of lipoplex nanoparticles. If it was so, development of a clearer and toxicity-free lipoplex solution was inevitable before projecting this formulation for potential clinical trials. For any clinical success, the injected materials should have least genotoxicity in subjects and should induce least or no signs of physiological discomfort and toxicity including any change in Ac ce pt ed M an u cr ipt\nbody weight. Towards achieving clinically translatable lipoplex exhibiting favorable toxicity and pharmacological effects, we replaced the D0, cationic lipid containing saturated aliphatic chains, as used in DXE-lipoplex with another cationic lipid (called D1) that contains a mono-unsaturated aliphatic chain. We renamed it as D1XE-lipoplex. Earlier it was demonstrated that oleoyldecanoyl-ethylphosphatidylcholine, bearing asymmetric behavior among hydrophobic tails due to the presence of mono-unsaturation in the hydrophobic core, in a transfection mixture as a co-lipid exhibited significantly better (50-fold) transfection efficiency compared to that of its symmetric counterpart bearing saturated aliphatic chains, i.e., stearoyldecanoylethylphosphatidyl choline (Koynova et al. 2006). Recently our group also demonstrated that liposome of mono-unsaturated cationic lipid-based formulations showed better transfection and fusogenicity than distearyl (having saturation in both the aliphatic chains) and dioleyl (having unsaturation in both aliphatic chains) analogue-based liposomal gene delivery systems (Meka et al. 2016). Clearly, a balance of symmetricity and asymmetric properties are required for better transfection. This study demonstrates the first ever comparison of genotoxicity profiles as well as therapeutic efficacies of two lipoplex nanoformulations respectively carrying saturated and unsaturated cationic lipids in mouse models. This kind of comparison is necessary to evaluate the clinical potential of any anticancer lipoplexes that exhibit initial preclinical successes and are to be projected for clinical trials and beyond."
    }, {
      "heading" : "Materials & Method",
      "text" : "All physicochemical, analytical and biological experiments, in vitro and in vivo, assays and their statistical calculations so performed were described in Supplementary Information."
    }, {
      "heading" : "Results",
      "text" : "Development of DXE and D1XE liposomal/lipoplex nanoformulations and their characterization\nWe developed two ESC8 and dexamethasone-associated cationic liposomal formulations, i.e., DXE and D1XE liposomes. DXE contains D0 (or DODEAC or N, N-bis(2-hydroxyethyl)-Noctadecyloctadecan-1-aminium chloride), which carries saturated aliphatic carbon chain. D1XE however contains D1 [(Z)-N, N-bis(2-hydroxyethyl)-N-octadecyloctadec-9-en-1-aminium chloride], which is an unsaturated cationic lipid owing to the presence of an oleyl (unsaturated) group [Scheme 1]. Both the formulations maintain a fixed molar ratio of constituents such as cationic lipid, cholesterol, dexamethasone and ESC8 [an anticancer drug, Scheme 1 (Sinha et al. 2011)] as 1:1:0.75:0.25. Using conventional lipid-hydration technique, the respective liposomes so developed were checked for hydrodynamic liposomal size, zeta potentials and, polydispersity index (PDI) in the presence and absence of serum. These two liposomal formulations show\nAc ce\npt ed\nM an\nus rip\nt\nnanometer (nm) range but variable sizes in water (135 to155 nm), serum free media (249 to 267 nm) and serum containing media (210 to 217 nm) [Table 1, Supplementary Fig. S1]. TEM analysis however shows that individual particles of respective formulations though have circular shape and are uniformly distributed but, DXE liposomes are bigger in size than D1XE liposomes [Supplementary Fig. S2]. HPLC analyses showed that the entrapment efficiency of ESC8 in DXE and D1XE liposomes are about 86% (data not shown)\nScheme 1. Molecular structures of saturated (D0) and unsaturated (D1) cationic lipids, dexamethasone and ESC8; Photographic representation of lipoplexes\nDXE and D1XE liposomes exhibiting positive zeta potential in serum-free media or in water make better electrostatic complexes with negatively charged plasmids (here, plasmid encodes anticancer gene, amiR-HSP90) to form respective lipoplexes. These lipoplexes exhibit bigger sizes than their respective liposomal form and bear negative zeta potential in the presence of cell culture media with or without serum [Table 1, Supplementary Fig.S3]. Notably, in absence of serum D1XE-lipoplex exhibits higher zeta potential than DXE-lipoplex. As a result, molecule to molecule interaction and hence flocculation will be evidently lesser in D1XE-lipoplex than DXE-lipoplex. As exhibited in scheme 1, D1XE lipoplex was significantly less translucent and less flocculent than DXE lipoplex. Corroboratively, DXE lipoplex showed significant variance in\nAc ce\npt ed\nM an\nus cr\nipt\ntheir size populations as indicated by higher polydispersity index (PDI) [Table 1]. Hydrodynamic size wise, D1XE-lipoplex is smaller than DXE-lipoplex.\nAssay and comparison of in vivo genotoxic effects in mice with lipoplexes\nIt is evident from previous study that the D1XE-lipoplex has favorable physical and biophysical properties than DXE-lipoplex. But it is important to review through preclinical studies the toxic effects (if any) of these lipoplexes and compare toward establishing its beneficial and potential clinical use. For this, we kept different groups of mice (males and females under each group), wherein two groups lipoplexes and the placebo or negative control (0.9% NaCl) were injected 7- times, but cyclophosphamide (CP), a known toxic, anticancer drug was injected in a standard amount only once. To compare the genotoxic effects due to single and multiple injections, we included two more groups: single injections of 0.9% NaCl and DXE-lipoplex. For all genotoxicity studies, the amount of respective lipoplexes’ contents including the encapsulated anticancer drug (ESC8, 3.73 mg/kg body weight) are same and equal to what has been tested in tumor-bearing mice. Before genotoxicity studies in bone marrow cells to begin, we accomplished cell cycle analyses of bone marrow cells of treated mice [Supplementary Fig. S4]. There in, we show that there are no significant changes in cell cycle pattern for control and D1XE-lipoplex treatment for both male and female populations. However, DXE-lipoplex, irrespective of gender, showed decreased number of G0/G1 phase cells and significantly increased numbers of G2/M phase cells compared to D1XE-lipoplex. CP induced much more G2/M arrests than all other groups. The data indicates that D1XE-lipoplex is relatively safer for bone marrows than DXEAc ce pt ed\nM\nan\nus cr\nipt\nlipoplex and CP. We also found that D1XE-lipoplex induced less intracellular ROS than DXElipoplex in CHO cells [Supplementary Fig. S5], clearly indicating that D1XE-lipoplex induces lesser ROS-induced clastogenic and aneugenic effects, especially on bone marrow cells.\nFollowed by cell cycle analyses, bone marrow and other cells isolated from mice of all these treated groups were then undergone the following studies:"
    }, {
      "heading" : "Chromosome aberration (CA)",
      "text" : "Chromosomal aberration (CA) assay was studied in mitotic metaphase chromosomes of bone marrow cells in groups as described above. The results are shown in Table 2 and the representative images types chromosomal damages analyzed are provided as Supplementary Fig. S6. The vehicle control group treated with 0.9% of NaCl showed very low occurrence of CA observed, where 8.33% in males and 4.49% in females. Contrastingly, the positive control groups treated with single dose of cyclophosphamide (CP) showed significantly higher percentage of aberrant metaphases (P < 0.001), percentage of aberrations including gaps (P < 0.001) and excluding gaps (P < 0.001). The single dose of DXE-lipoplex showed a considerably higher number of CAs relative to vehicle control both in males (p<0.01) and in females (p<0.001) mice. In this group, the CAs were mostly in the form of chromatid gaps and breaks and to an insignificant level in the form of chromosomal breaks and fragments (more pronounced in females). Interestingly, the group of mice those treated with multiple doses of DXE-lipoplex, the incidence of CAs was negligible and the genotoxic effects were significantly reduced as compared to the groups of mice, which received the single dose treatment of DXE-lipoplex. On the other hand, multiple doses of D1XE-lipoplex also showed significantly lesser CAs, mostly in the form of chromatid gaps compared to both single and multiple doses of DXE-lipoplex with 20.8% in males and 20.7% in females, thus demonstrating a thoroughly superior compatibility and much less gender-biasness with D1XE-lipoplex over DXE lipoplex. Fig.1. shows the fold change of CA w.r.t. control in different treatment groups. While single dose of DXE-lipoplex treatment shows 2 folds lesser CA compared to CP, multiple doses of DXE-lipoplex shows a four-fold decrease and multiple doses of D1XE-lipoplex shows a further pronounced effect with a six-fold decrease in CA (Fig 1A). Although the difference in fold change of aberrant metaphases including gaps (Fig 1B) between multiple doses of DXE- and D1XE-lipoplex treatment groups is insignificant, a significantly decreased fold change of CA can be observed in D1XE-lipoplex treated group as compared to DXE-lipoplex treated group when gaps were excluded (Fig 1C), showing a reduced toxic effect (if any) of D1XE lipoplex as compared to DXE lipoplex. Clearly, in all parameters of CA, D1XE lipoplex, with respect to DXE lipoplex, induces relatively lesser aberrations in metaphases as well as aberrations with or without gaps Notably, we did not notice any significant gender-biasness in lipoplex treatment-related toxicity in this study. Ac ce pt ed M an us cr ipt\nTable 2. Frequency of chromosomal aberrations observed in bone marrow cells of male and female Swiss albino mice after 24 hrs following single and multiple doses of 0.9% NaCl, cyclophosphamide and DXE-amiR-Hsp90 and D1XE-amiR-Hsp90 lipoplexes\nb.w.: body weight; s: single dose; m: multiple doses; ctd: chromatid; cm: chromosome; G: gaps; B: breaks; F: fragments; M: minutes; Pul: Pulverization; T: Translocation; M ± S.E.M: Mean ± Standard error of mean; 0.9 % NaCl: Control; CP: cyclophosphamide (Positive control); ns: Non-significant; * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001 [p values so depicted are with respect to vehicle control].\nChemicals\nused\nDose\n(mg/kg\nb.w.)\nsingle (s)/ multiple\n(m)\nNumber of mice treated\nand\ngender\nNo. of\nmetaphase\nSpreads observed\nNo. of\naberrant\nMetaphase\nspreads\nTypes and no. of aberrations\n% of\naberrant\nmetaphases\nno of\naberrations\nincluding\ngaps\n% of\naberrations\nincluding\nGaps\n% of\naberrations\nexcluding\ngaps ctd Cm\nF m Pul G B G B\n0.9% NaCl\n0.9% (s)\n3 ♂ 600\n50 22 21 3 2\n8.33 0.67 43 7.161.16 3.99 0.66\n3 ♀ 600\n30 15 17\n4.49 0.16 32 4.49  0.16 2.83 0.17\n0.9% NaCl\n0.9% (m)\n3 ♂ 700 61 27 27 3 0 0 0 0 10.1 ± 2.47 60 5.44 ± 1.37 4.33 ± 0.88 3 ♀ 700 59 24 26 1 2 0 0 0 9.67 ± 2.17 56 4.44 ± 1.28 4.89 ± 1.16\nDXEamiRHsp90\n3.73 (s)\n3 ♂ 950\n300 212 187 3 17 7 4\n0 32.57 \n5.39 ** 454\n50.44  5.98\n26.22  2.45**\n3 ♀ 906\n404 387 336 9 15 12 5\n0 44.54 \n4.13 793\n87.39  10.18 \n42.74 6.91\nDXEamiRHsp90\n3.73 (m)\n3 ♂ 600 209 146 106 4 3 6 1 0\n34.8 ±\n3.44*** 275\n25.7 ±\n1.01***\n20.2 ± 5.40*\n3 ♀ 600 180 159 84 7 5 1 0 0\n30.0 ± 3.62** 268\n28.8 ± 2.96** 15.8 ± 4.23\nD1XEamiRHsp90\n3.73 (m)\n3 ♂ 600 125 116 68 3 5 2 0 0\n20.8 ± 0.441 202\n20.3 ± 2.46**\n13.3 ± 2.13\n(ns)\n3 ♀ 600 124 154 38 7 1 2 0 0\n20.7 ± 2.89* 210\n28.0 ± 3.12** 7.00 ± 1.26\nCP\n40 (s)\n3 ♂ 900 455 60 795 8 61 48 9 12\n50.6 ±\n5.30*** 1179\n131 ±\n4.34***\n123 ±\n4.28***\n3 ♀ 900 470 120 899 4 31 58 8 14\n52.2 ±\n1.11*** 1300\n144 ± 2.06\n*** 130 ±\n3.02***\n\nAc ce\npt e\nM an\nus cr\nipt\nFigure 1. Fold changes for chromosomal aberrations with respect to negative control (0.9% NaCl) for in vivo chromosomal aberration assay in bone marrow cells of Swiss albino mice:(A) Total number of aberrant metaphases, (B) Total number of aberrations including gaps, and (C) Total number of aberrations excluding gaps. Chromosomal aberration studies were performed in 3 male and 3 female mice. Triplicate sample-slides were made from each mouse. A minimum of 300 mitotic metaphases were screened from each animal to analyze the different types of chromosomal aberrations. Fold changes among percentages of chromosomal aberrations (w.r.t. control) represented for combined groups of male and female mice that received multiple doses (7 alternate doses for 14 days) of DXE-amiR-Hsp90 (3.73 mg/kg b.w.) and D1XE-amiR-Hsp90 (3.73 mg/kg b.w.) and single dose of CP (40 mg/kg b.w.) as positive control and DXE-amiRHsp90 (3.73 mg/kg b.w.) respectively.\nMitotic Index (MI) study from Bone marrow cells\nMitotic indices (MI) for respective treatment groups were calculated based on the observation in bone marrow cells of male and female Swiss albino mice after 24 hours following treatment with single and multiple doses of control, DXE- and D1XE lipoplexes and cyclophosphamide (Table 3). Both DXE- and D1XE-lipoplexes at multiple doses showed similar but significantly increased percentage of mitotic index than other treatment groups and were closer to MI values for single dose of negative control. Ironically, multiple doses of negative control exhibited lower MI than those of multiple doses of DXE- and D1XE-lipoplexes respectively. Single dose of positive control (CP) exhibited least MI in both male and female treatment groups. DXE-lipoplex at single dose showed less percentage of MI as compared to single dose of negative control. The graphical representation of fold changes of mitotic indices as compared to negative control in different treatment groups are shown in Fig.2. Multiple doses of DXE- and D1XE-lipoplexes show approximately two-fold and six-fold greater percentage of mitotic index as compared to Ac ce\npt\ned\nM nu\ncr\nipt\nmultiple doses of negative and single dose of positive controls respectively, indicating the nontoxic nature of the lipoplexes in bone marrow cells. Corroborating earlier data on CA, in the multiple doses of lipoplex, an increased number of cells at mitotic stage were observed which reflects that the cells were prevented to move out of G2/M phase. At this stage, those cells which acquired the damages at G1 phase finally accumulated at G2/M phase for DNA repair, thereby resulting in the increase in the percentage of dividing cells compared to control. In this study as well, we did not notice any selective gender-biasness in lipoplex-treatment related toxicity.\nTable 3. Mitotic index: Changes in mitotic index observed in bone marrow cells of male and female Swiss albino mice after 24h following single and multiple doses of 0.9% NaCl, Cyclophosphamide and DXE-amiR-Hsp90 and D1XE-amiR-Hsp90 lipoplexes.\nb.w.: body weight; MI: Mitotic Index; 0.9 % NaCl: Control; CP: cyclophosphamide (Positive control); s: single dose; m: multiple dose; ± indicates S.E.M: Mean ± Standard error of mean; ns: Non-significant; * indicates p<0.05; **indicates p< 0.01 [p values so depicted are with respect to vehicle control].\nName of the compound Dose (mg/Kg b.w.) Number of mice\ntreated and gender\nTotal no. of the cells examined Total no. of dividing cells observed Percentage of Mitotic index\n0.9% NaCl 0.9% (s) 3 ♂ 4118 221 5.3  0.20\n3 ♀ 4103 233 5.6 0.20\n0.9% NaCl 0.9% (m)\n3 ♂ 6176 204 3.30 ±0.29 3 ♀ 6042 212 3.51 ±0.82\nDXE-amiRHsp90 3.73 (s)\n3 ♂ 6715 265 3.9  0.30  3 ♀ 6253 283 4.30.48 ns\nDXE-amiRHsp90 3.73 (m)\n3 ♂ 6541 311 4.75 ± 0.09* 3 ♀ 6648 321 4.83 ± 0.06\nD1XE-amiRHsp90 3.73 (m)\n3 ♂ 6310 280 4.44 ± 0.56 3 ♀ 6610 279 4.22 ± 0.31\nCP\n40 (s)\n3 ♂ 6106 135 2.21 ± 0.08** 3 ♀ 6326 124 1.96 ± 0.02**\nAc ce\npt ed\nM an\nus cr\nipt\nMicronucleus (MN) tests on polychromatic erythrocytes (PCE) from bone marrow and peripheral blood\nMN test detects the clastogenic and anagenic potential of the chemical on PCEs. These MNs are formed due to acentric fragments, whole chromosomes or chromatids during mitotic division process. Two different sources were considered for the analysis of MN, i.e. PCEs from bone marrow and peripheral blood after 30 hrs following single or seven alternative day injections with different treatment groups of 0.9% NaCl, and DXE-lipoplexes, seven injections of D1XElipoplexes and single injection of Cyclophosphamide."
    }, {
      "heading" : "MN test on bone marrow",
      "text" : "Table 4 represents the results of bone marrow micronucleus assay [representative images are provided as Supplementary Fig. S7 A-B] in male and female groups of Swiss albino mice after 24h following treatment of single and multiple doses of 0.9%NaCl, DXE-, D1XE-lipoplexes and cyclophosphamide. Single dose of cyclophosphamide treated male and female mice showed significantly higher number of MNs per 1000 PCEs in male, 25.24 (p<0.001) and in female, 26.56 (P<0.001) compared to the 0.9% NaCl treated male (2.66) and female (3.06) mice per 1000 PCEs. DXE-lipoplex treated groups showed significant difference in number of MN as compared to positive and negative controls at both single and multiple doses respectively in male 7.41 (p<0.01) and 7.88 (p<0.001) and in female mice 7.53 (p<0.01) and 5.55(p<0.05) respectively. However, in groups treated with multiple doses of D1XE-lipoplex, a significant difference in MN relative to control could not be observed in both male (3.54) and female (3.40) mice indicating the potential non-toxic nature of D1XE lipoplex in bone Ac ce\npt ed\nM nu\nsc rip\nt\nmarrow cells as compared to the remaining treatment groups. Altogether, multiple doses of both DXE- and D1XE-lipoplexes show approximately five-fold lesser percentage of MN as compared to single dose of CP (Fig 3). Clearly once more it is evident that D1XE-lipoplex shows negligible detrimental effect on PCEs obtained from bone marrow and hence is relatively better and safer than DXE-lipoplex to use in vivo. In this study also, gender biasness was largely absent between lipoplexes’ treatment-related toxicities, except in multiple injections of DXE-lipoplex.\nFigure 3. Fold change of micronucleus (w.r.t. control) in bone marrow cells of Swiss albino mice. Analysis of micronuclei number in bone marrow cells was done in 3 male and 3 female mice. A minimum of 2000 polychromatic erythrocytes (PCE) were screened per animal.\nMN analysis of peripheral blood\nTable 5 represents the results of peripheral blood micronucleus assay [representative images are provided as Supplementary Fig.S7 C-D] in male and female groups of Swiss albino mice after 30h following treatment of single and multiple doses of 0.9%NaCl, DXE, D1XE lipoplexes and cyclophosphamide. Single dose of cyclophosphamide treated male and female mice showed significantly higher number of MNs per 1000 PCEs in male, 19.23 (p<0.001) and in female, 21.78 (P<0.001) compared to the 0.9% NaCl treated male (2.52) and female (3.22) mice. While the single dose, DXE-lipoplex treated group showed a relatively significant difference compared to negative and positive controls in peripheral blood MN in male 7.3 (p<0.001 compared to control and p<0.01 compared to CP) and female 8.19 (p<0.01 compared to control and p<0.05 compared to CP). However, multiple doses of DXE-lipoplex induced significantly less of MN in peripheral blood PCEs among male (3.19) and female (2.23) mice. However, in groups treated with multiple doses of D1XE lipoplex, irrespective of genders, a relatively less number of MN with respect to negative control was observed. Further, D1XElipoplex treatment exhibited significantly less number of MN compared to MN observed following CP-treatment. Altogether, multiple doses of both DXE- and D1XE-lipoplexes respectively show almost six and nine-folds lesser percentage of MN when compared to single dose of CP (Fig 4). In overall, the data is consistent to indicate the potential non-toxic and biocompatible nature of D1XE-lipoplex for even multiple injections. As observed earlier, we failed to see any gender related biasness among the treated groups in this study also. Ac ep te d\nM an\nus\ncr\nipt\nb.w.: body weight; 0.9 % NaCl: Control; CP: cyclophosphamide (Positive control);s: single dose; m: multiple dose; PCE: Polychromatic erythrocytes; MN: Micronuclei; PB-MN: peripheral blood micronuclei; ± indicates S.E.M: Mean ± Standard error of mean; *** indicates p<0.001; ** indicates p< 0.01; * indicates p< 0.05 [p values so depicted are with respect to vehicle control].\nAc ce\npt ed\nFigure 4. Fold change of Micronuclei number (w.r.t control) in peripheral blood cells of swiss albino mice. Analysis of micronuclei number in peripheral blood cells was done in 3 male and 3 female mice. A minimum of 2000 polychromatic erythrocytes (PCE) were screened per animal.\nSingle cell gel-electrophoresis assay The results of comet assay [representative images are provided as Supplementary Fig.S8] in male and female mice after 24hrs following single and multiple doses of 0.9%NaCl, DXE-, D1XE-lipoplexes and cyclophosphamide are represented in Table 6. Single dose of CP showed significantly higher percentage of tail DNA in female [10.36% (p<0.0001) in bone marrow cells, and 28.29% (p<0.0001) in blood cells] and male [12.36% (p<0.0001) in bone marrow cells and 30.18% (p<0.0001) in blood cells] mice in comparison to 0.9% NaCl treated female (2.29 % bone marrow and 4.77% in blood) and male (3.25% in bone marrow and 5.59% in blood) mice. While the single dose of DXE-amiR-Hsp90 treated groups showed higher percent of tail DNA in female [7.37% (p<0.0001) in bone marrow and 10.25% (p<0.001) in blood cells] and in male [8.20% (p<0.0001) in bone marrow and 13.25(p<0.0001) in blood cells] mice in comparison to control. It seems that single dose of DXE-lipoplex imparts similar level of toxicity to both bone marrow and peripheral blood. Multiple doses of DXE-lipoplexes also showed enhanced percentages of tail DNA in female [5.24% (p<0.01) in bone marrow cells and 11.31% (p<0.0001) in blood cells] and male [5.64% (p<0.01) in bone marrow cells and 10.04% (p<0.01) in blood cells] mice. However, multiple doses of D1XE lipoplex treated female [3.56% in bone marrow cells and 6.12% in blood cells] and male [4.41% in bone marrow cells and 7.19% in blood cells] mice showed insignificant percentages of tail DNA compared to control group. Overall, multiple doses of both DXE and D1XE lipoplexes show approximately two- and four-folds lesser percentage of tail DNA respectively as compared to single dose of CP (Fig 5), indicating the better biocompatibility of D1XE over DXE lipoplex. Ac e te d M an\nus\ncr\ni t\nIn this study, barring the group with single injection of DXE-lipoplex, no other treatment groups showed any signs of gender-biasness among treatment-related toxicities.\nb.w.: body weight; 0.9 % NaCl: Control; CP: Cyclophosphamide (Positive control); s: single dose; m: multiple dose; ± indicates: Standard deviation; ns: non-significant; *** indicates p< 0.001; ** indicates p< 0.01[p values so depicted are with respect to vehicle control].\nAc ce\npt e\nThe liposome to plasmid charge ratio was maintained at 2:1 for both lipoplexes and contained 3.85μM ESC8 and 0.3µg amiR-Hsp90 plasmid per well. Both the lipoplexes showed substantial cancer-cell specific cytotoxicity and negligible toxicity in normal cell lines after 48h of treatment (Fig. 6). However, except in MIA PaCa-2, respective cytotoxicities of D1XE-amiR-Hsp90 lipoplex against PANC-1 and B16F10 were significantly higher than DXE-amiR-Hsp90 lipoplex. The reason for better anticancer effect of D1XE-lipoplex could be that D1XE-lipoplex has relatively better transfection efficiency and much higher cellular uptake in cancer cells compared to DXE-lipoplex [Supplementary Figs. S9 and S10]. As indicated in Fig. 6 both the lipoplexes have insignificant cytotoxic effects toward normal cells. Thus, the data in overall indicate that lipoplexes indeed induce cancer cell-selective cytotoxicity in cancer cells.\nAc ce\npt ed\nM an\nus cr\nipt\nAnti-tumor and pro-survival effect of lipoplexes\nDXE-anti-miR HSP90 and D1XE-anti-miR HSP90 have shown selectivity in their cytotoxic activity against cancer cells over non-cancer cells. In order to determine their effect on in situ tumor in mouse model, we developed melanoma tumor model in mice by inoculating mouse melanoma cells, B16F10 in C57BL6 mice. On 11 th day since inoculation of tumor cells when tumors were palpable and are about 100 mm 3 in size, both the anticancer lipoplexes were respectively injected through intraperitoneal (IP) route to different groups of mice. However, visual observation of both the lipoplexes clearly shows distinctly different characters with D1XE-lipoplex being less flocculent and more transparent than DXE-lipoplex (photographic representation in Scheme 1). The treatment continued every alternate day and a total of 7 injections were performed. As a control 5% glucose was also administered in a separate group (called untreated or UT) of tumor-bearing mice. Clearly, the lipoplexes have significant antitumor effects. The effect is evident visually in representative tumor isolated from sacrificed mice belonging to respective treatment groups (Fig. 7A). Among the lipoplexes, D1XE-lipoplex showed better anti-tumor effect compared to DXE-lipoplex (Fig. 7B). Further, the therapeutic efficacy was compared by performing TUNEL assay and Ki67 staining of tumor sections from sacrificed mice of DXE- and D1XE-lipoplex treated groups [Supplementary Fig. S11-S12]. TUNEL assay reveals the extent of apoptosis induction and Ki67 staining marks the extent of proliferating cells presents. Tumors of D1XE-lipoplex treated group have evidently more pronounced apoptotic cells and lesser number of proliferative cells than in tumors of DXElipoplex treated group. D1XE-lipoplex pronouncedly increased the life-time of mice compared to mice treated with DXE-lipoplex and those from UT group (Fig. 7C). Moreover, possible Ac ce pt d M an\nus cr\nipt\ndetrimental effect on mice due to multiple doses of DXE-lipoplex was evident from the reduced body weight of both male and female mice. This was in contrast to the effect so obtained on mice following multiple doses of D1XE-lipoplex [Supplementary Fig.S13]. In overall, it is clear that the presence of unsaturated lipid in anticancer lipoplex has more anti-tumor effect, induce more survivability and with least detrimental effect on overall well-being of mice than when lipoplex carries saturated lipid in anticancer lipoplex.\nFigure 7. In vivo tumor regression and survival analysis of mice treated with D1XE lipoplex relative to DXE lipoplex and untreated groups. C57BL/6J mice with subcutaneously inoculated B16F10 mouse melanoma tumor received lipoplexes intraperitoneal injections starting from the 11 th day of tumor inoculation, when the tumors were palpable. Mice in respectively three groups were injected with 5% glucose (UT), DXE-amiR-Hsp90 lipoplex and D1XE-amiR-Hsp90 lipoplex were given every alternate day starting from day 11 of tumor inoculation to day 23 (represented by arrows). Each group consisted of 5 mice. A. Representative image of isolated tumor mass from different treated groups showing significant tumor volume reduction by D1XE lipoplex relative to DXE lipoplex and untreated groups. B. Tumor volume regression curve showing significant reduction in tumor volumes in groups treated with DXE and D1XE lipoplexes relative to untreated (UT) group. C. Survivability plot showing enhanced survival of tumor-bearing mice upon D1XE lipoplex treatment relative to DXE lipoplex-treated and untreated mice."
    }, {
      "heading" : "Discussion",
      "text" : "Liposome mediated drug delivery systems for the treatment of cancers are well known and many of the delivery systems are in clinics or in clinical trials against many cancers (Chang et al. 2012, Pattni et al. 2015). Among cationic lipid-based liposomal drug delivery system for cancer, formulations called EndoTAG-1& EndoTAG-2 are in respective clinical trials (Eichhorn M.E. et al. 2006, Eichhorn M. E. et al. 2010, Hua et al. 2012). The formulations use a cationic lipid called DOTAP, which carries two unsaturated aliphatic long chains. Other drug delivery systems\nAc c\npt ed\nM an\nus cr\nipt\ncarrying unsaturated and saturated cationic lipids are also used (Immordino et al. 2006). One of the common negative perception about using cationic lipids clinically is that these lipids induce suspected non-specific toxicity following repeated administration. As this is suspected to be associated with the induction of complement activation and co-stimulatory immune reactions besides their non-specific electrostatic interaction/binding with membrane surface of organs. Clearly, prior to clinical trials, any such detrimental effects of cationic lipid-associated formulations, critically in bone marrow cells, have to be estimated before applying for investigative new drug (IND) filing. We have previously shown the effect of the presence of number of unsaturated aliphatic chains with respect to saturated chains on gene delivery aspects (Meka et al. 2016). In there, we showed that a balance of both saturation and unsaturation in aliphatic chain favors efficient gene transfection outcome. Needless to say, a favorable cellular gene transfection pre-mandates absence of transfection agent-mediated toxicity of any form, evidently within the experimental time. However, no further evaluations of toxicological effects are generally performed unless the formulation shows critical preclinical efficiency. Before us, normal DOTAP liposome (a lipid with two unsaturated aliphatic chain) was evaluated for its toxicity in vivo, only to find some level of genotoxicity in lung and spleen. Those genotoxicities would have remained undetected, had those studies not done in the face of the fact that histological and hematological evaluation of organ and blood parameters were largely normal (Knudsen et al. 2015). Clearly, a full genotoxicological evaluations, especially of bone marrow cells from treated subjects are needed as a part of pre-IND studies for any clinically potential, drug-laden cationic liposomal formulations. Moreover, to our knowledge, before this study systemic genotoxicological evaluations of clinically projected liposomal delivery systems, focusing solely on the number of saturation/unsaturation in aliphatic chains are never performed. Hence, we chose to compare genotoxicological parameters as well as therapeutic efficiencies of two anticancer drug and gene carrying cationic lipid-associated delivery systems, wherein the cationic lipids are largely same, except for their structural variance due to the presence or absence of unsaturation in one of the aliphatic chains. In the present study, we chose two cationic lipoplex (lipid-DNA complex) formulations that carry the same anticancer drug and an anticancer gene-encoded plasmid. The formulations carry either D0 (both aliphatic chains saturated) or D1 (one aliphatic chain unsaturated and the other saturated) cationic lipid respectively. D0-lipid associated, anticancer lipoplex (DXE-lipoplex) was previously tested to act against pancreatic cancer, melanoma and breast cancer stem cells (Ahmad et al. 2016) with no visible toxicological effect. No systemic genotoxicological effects were however performed earlier with that formulation. But, while evaluating antitumor efficacy of DXE-lipoplex in tumor bearing mice, we could notice a visible occurrence of temporary lethargy among treated mice only after 1 st injection. The slower mobility of mice became normal next day and following all subsequent injections. However, the treated mice exhibited some weight loss at the end of study, clearly indicating that even though the formulation was Ac ce pt d M an us cr ipt\ntherapeutically efficient but it apparently induced moderate level of toxicity. Any formulation projected to undergo clinical trials and branded safe for trials may have high therapeutic efficiency but should have least toxicity on subjects, i.e., increasing higher therapeutic index. Toward establishing a trial-safe formulation, we redesigned the constituents. Keeping all parameters same, we replaced D0 with D1. We find notable difference between the two lipoplexes. Owing to the presence of unsaturation, the D1XE-lipoplex aqueous formulation becomes lesser opaque, lesser rigid than DXE-lipoplex and becomes easily injectable in both IP and IV mode of injection compared to DXE-lipoplex. It is known that cell membrane surface is negatively charged. Owing to its closer to neutral zeta potential in serum-associated media, D1XE-lipoplex compared to DXE lipoplex was expected to have more cell membrane interaction. Compounded with fusogenic property of unsaturated lipid, the overall capability of D1XE-lipoplex to fuse/interact with cell membrane was logically higher than DXE-lipoplex. Herein, we chose to check the genotoxicological profiling as not much of this profiling was critically studied earlier to check the safety of a cationic lipid-based formulation. Moreover, based on our earlier observation about the induction of lethargy in mice following first injection of DXE-lipoplex, we kept a single injection DXE-lipoplex-treatment group also. The positive control group, i.e., single injection of cyclophosphamide-treatment induced maximum genotoxicity in mice in all tested parameters. Surprisingly, the next highest genotoxic effect was induced by ‘DXE-lipoplex single injection treatment’. The genotoxic effects were significant compared to ‘DXE-lipoplex multiple injections treatment’. Multiple times injection of D1XElipoplex however induced minimum genotoxicity and in some parameters, it is even significantly less toxic compared to multiple injections of DXE-lipoplex. As we observed, multiple dose treatment of DXE-lipoplex induced much less CAs than single dose treatment. This clearly denotes that the mice with single dose lipoplex treatment incurring any form of CAs may be reversible. With multiple lipoplex doses the mice show the sign of tolerability against any form of transient genetic changes that reverses back to normalcy. Frequency of CAs due to lipoplex of single dose was found to be more than the multiple doses. The time period for evaluation of CAs used to be 24 h post-treatment. Hence, following single injection, the cells carrying the chromosomal damages were not able to enter next cell cycle and also there was no time for the cells to undergo DNA repair. Whereas, up to penultimate injection in multiple dose treatment, there were sufficient time for the cells to undergo DNA repair. Even grossly affected cells might have undergone apoptosis before entering into the next level of cell division. Hence, in our study, we found higher frequency of CAs in single dose compared to multiple dose of lipoplex. Apart from this, in both single and multiple doses of lipoplex, majority of CAs were with chromatid gaps and breaks out of which their number was more in the single dose of DXE-lipoplex. This higher number of chromatid types of aberrations in the single dose may be due to the enhancing mitogen stimulated DNA synthesis thereby induction more number of chromatid types of aberrations. Whereas, multiple of doses prolonged the DNA synthesis and provided sufficient time for cells to repair induced DNA damages. Hence, there was significantly lesser number of Ac ce pt ed M an us cr ipt\nchromosomal damages as well as decreased number of chromatid types of aberrations noticed in those mice receiving multiple doses of DXE or D1XE-lipoplexes.\nThus, following the treatments of lipoplexes, especially for multiple doses, any early signs of damages are well repaired and the mice is acquainted to the early shock due to first injection. If it is so, the damages due to DXE-lipoplex in true sense is minimal. This is corroborated by the micronuclei test wherein, multiple doses of both lipoplexes showed higher toxic effect in the bone marrow cells compared to peripheral blood cells. This implies that the damages so occurred in bone marrow cells are either being repaired or the grossly damaged cells might have been eliminated (apoptosis) before reaching the cells from bone marrow to peripheral blood leaving lesser cells with micronucleus in peripheral blood. Alternatively, it could be due to the fact that in the peripheral blood, the grossly affected cells might have eliminated selectively by the spleen, thus resulting in a lesser number of micronuclei in peripheral blood compared to bone marrow cells. In comet assay however, the trend was opposite indicating that damaged, apoptotic cells were not completely cleared from peripheral blood cells as soon as the experiments were terminated 24h post injections. The increased level of DNA damages in peripheral blood may be related to repeated interaction of circulating lipoplex with the blood cells for a longer duration. The other possibility could be that a higher number of damaged cells escaped the apoptosis from bone marrow that were found in peripheral blood. But, regaining of MI in bone marrow cells following multiple injections of both the lipoplexes and getting closer to or better than MI in bone marrow cells obtained from negative control (0.9% NaCl) group, clearly indicates reversal of any impending damages in bone marrow cells towards normalcy.\nIn the overall genotoxicological profiling, multiple injections of D1XE-lipoplex had the least detrimental effect on mice and showed values closest to values obtained from negative control group, be it chromosomal aberration, mitotic index, number of micronucleus test among polychromatic erythrocytes, cell cycle analysis, or tail DNA analyses from bone marrow and peripheral blood cells. It is also noteworthy that there is largely no gender biasness in treatmentrelated toxicities, more so for the D1XE-lipoplex treated group. In melanoma tumor model in mice, the D1XE-lipoplex solution (visibly showing less opaqueness and hence more solubility) showed better tumor regression and importantly, induced more survivability in tumor-bearing mice. Thus, the higher survivability of mice can be attributed to two main factors: a) more efficient regression of aggressive tumor growth leaving less tumor burden for a given time point; b) lesser treatment-related toxicity accompanying the tumor treatment.\nEvidently, one could see the difference in activities, physicochemical, toxicological and therapeutic, of both the lipoplexes in spite of an apparently small structural change of one of the lipid constituents. Hence, the anticancer lipoplex that carried cationic lipid of one unsaturation in its aliphatic chain exhibited the most efficient therapeutic output and least genotoxicity.\nAc c\npt ed\nM an\nsc rip\nt\nIn conclusion, this study indicates that a minute change as low as a simple inclusion of an unsaturated C-C bond moiety in aliphatic chain of cationic lipids as one of the constituents in an anticancer drug-carrying lipoplex favors better therapeutic index than when same lipoplex carries a cationic lipid of saturated aliphatic chains. This critical observation is important and demands a relook into the formulation aspects among cationic lipid-based anticancer therapeutics, which are projected or expected to hit clinical trials."
    }, {
      "heading" : "Acknowledgement",
      "text" : "The study is supported by Council of Scientific & Industrial Research (CSIR), Govt. of India funds [CSC0302, CMPP03] (to RB), Indian Council of Medical Research (ICMR), Govt. of India funds[45/15/2018-PHA/Toxi/BMS/OL & 45/16/2018-PHA/Toxi/BMS/OL] (to SM). HKR, SKM, KS, MMCSJ, SJ acknowledge CSIR and SD, KJ acknowledge ICMR for their respective doctoral fellowships. VB acknowledges CSC0302 for his project fellowship."
    }, {
      "heading" : "Other information and disclosure",
      "text" : "This is CSIR-IICT communication No. IICT/Pubs./2019/061. The authors disclose no conflict of interest in any form."
    }, {
      "heading" : "1• Issue 3• 2012 techniques is to obtain efficient drug entrapment and increase stability of the liposome",
      "text" : "products [52]. Most of drugs listed in Table 1. Conde J, Larguinho M, Cordeiro A, Raposo LR, Costa PM, Santos S, Diniz MS, Fernandes AR, Baptista PV. 2014. Gold-nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis. Nanotoxicology 8:521-532. Deshpande PP, Biswas S, Torchilin VP. 2013. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 8:1509-1528. Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Teifel M, Ruhstorfer H, Michaelis U, Griebel J, Brix G. 2006. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer biology & therapy 5:89-96. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U. 2010. Vascular targeting by EndoTAG™‐1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. International journal of cancer 126:1235- 1245. Hua J, Gross N, Schulze B, Michaelis U, Bohnenkamp H, Guenzi E, Hansen LL, Martin G, Agostini HT. 2012. In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. Molecular vision 18:1045. Ac pt ed M\nan us\ncr ipt\nImmordino ML, Dosio F, Cattel L. 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine 1:297. Knudsen KB, Northeved H, Ek PK, Permin A, Gjetting T, Andresen TL, Larsen S, Wegener KM, Lykkesfeldt J, Jantzen K. 2015. In vivo toxicity of cationic micelles and liposomes. Nanomedicine: Nanotechnology, Biology and Medicine 11:467-477. Koynova R, Wang L, MacDonald RC. 2006. An intracellular lamellar–nonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents. Proceedings of the National Academy of Sciences 103:14373-14378. Lee SM, Kim JS, Oh YK, Lee YB, Sah H. 2005. Biodistribution and genotoxicity of transferrin-conjugated liposomes/DNA complexes in mice. Macromolecular Research 13:218-222. Marepally S, Chandrashekhar V, Reddy RC, Prabhakar R, Bojja S, Chaudhuri A. 2011. The influence of the structural orientation of amide linkers on the serum compatibility and lung transfection properties of cationic amphiphiles. Meka RR, Godeshala S, Marepally S, Thorat K, K. RRH, Dhayani A, Hiwale A, Banerjee R, Chaudhuri A, Vemula PK. 2016. Asymmetric cationic lipid based non-viral vectors for an efficient nucleic acid delivery. RSC Advances 6:77841-77848. Mondal SK, Jinka S, Pal K, Nelli S, Dutta SK, Wang E, Ahmad A, AlKharfy KM, Mukhopadhyay D, Banerjee R. 2016. Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors. Mol Pharm 13:2507-2523. Pattni BS, Chupin VV, Torchilin VP. 2015. New Developments in Liposomal Drug Delivery. Chemical Reviews 115:10938-10966. Pore SK, et al. 2013. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect. Biomaterials 34:6804-6817. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. 2018. Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications 9:1410. Sinha S, et al. 2011. A Lipid-Modified Estrogen Derivative that Treats Breast Cancer Independent of Estrogen Receptor Expression through Simultaneous Induction of Autophagy and Apoptosis. Molecular Cancer Research 9:364-374. Vasievich EA, Chen W, Huang L. 2011. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother 60:629-638. Xie H, Mason MM, Wise JP, Sr. 2011. Genotoxicity of metal nanoparticles. Rev Environ Health 26:251- 268. Zylberberg C, Gaskill K, Pasley S, Matosevic S. 2017. Engineering liposomal nanoparticles for targeted gene therapy. Gene Ther 24:441-452.\nAc ce\npt ed\nM an\nus cr\nipt"
    } ],
    "references" : [ {
      "title" : "Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model",
      "author" : [ "A Ahmad", "SK Mondal", "D Mukhopadhyay", "R Banerjee", "KM. Alkharfy" ],
      "venue" : "Molecular pharmaceutics 13:1081-1088. Alexander JF, Aguirre-Villarreal D, Godin B. 2017. Liposomal encapsulation masks genotoxicity of a chemotherapeutic agent in regulatory toxicology assessments. Nanomedicine 13:829-833.",
      "citeRegEx" : "Ahmad et al\\.,? 2016",
      "shortCiteRegEx" : "Ahmad et al\\.",
      "year" : 2016
    }, {
      "title" : "Nanoparticles in the clinic",
      "author" : [ "AC Anselmo", "S. Mitragotri" ],
      "venue" : "Bioeng Transl Med 1:10-29. AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. 2009. Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells. ACS Nano 3:279-290. Bulbake U, Doppalapudi S, Kommineni N, Khan W. 2017. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9.",
      "citeRegEx" : "Anselmo and Mitragotri,? 2016",
      "shortCiteRegEx" : "Anselmo and Mitragotri",
      "year" : 2016
    }, {
      "title" : "Clinically-Proven Liposome-Based Drug Delivery: Formulation, Characterization and Therapeutic Efficacy",
      "author" : [ "H Chang", "M Cheng", "M. Yeh" ],
      "venue" : "1: 195. doi: 10.4172/scientificreports. 195 Page 2 of 8 Volume 1• Issue 3• 2012 techniques is to obtain efficient drug entrapment and increase stability of the liposome products [52]. Most of drugs listed in Table 1. Conde J, Larguinho M, Cordeiro A, Raposo LR, Costa PM, Santos S, Diniz MS, Fernandes AR, Baptista PV.",
      "citeRegEx" : "Chang et al\\.,? 2012",
      "shortCiteRegEx" : "Chang et al\\.",
      "year" : 2012
    }, {
      "title" : "Gold-nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis",
      "author" : [ "PP Deshpande", "S Biswas", "VP. Torchilin" ],
      "venue" : "Nanotoxicology",
      "citeRegEx" : "2014",
      "shortCiteRegEx" : "2014",
      "year" : 2013
    }, {
      "title" : "Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging",
      "author" : [ "G." ],
      "venue" : "Cancer biology & therapy 5:89-96. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U. 2010. Vascular targeting by EndoTAGTM‐1 enhances therapeutic efficacy of",
      "citeRegEx" : "G.,? 2006",
      "shortCiteRegEx" : "G.",
      "year" : 2006
    }, {
      "title" : "conventional chemotherapy in lung and pancreatic cancer. International journal of cancer",
      "author" : [ "J Hua", "N Gross", "B Schulze", "U Michaelis", "H Bohnenkamp", "E Guenzi", "LL Hansen", "G Martin", "HT. Agostini" ],
      "venue" : "Molecular vision 18:1045",
      "citeRegEx" : "Hua et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Hua et al\\.",
      "year" : 2012
    }, {
      "title" : "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential",
      "author" : [ "ML Immordino", "F Dosio", "L. Cattel" ],
      "venue" : "International journal of nanomedicine 1:297. Knudsen KB, Northeved H, Ek PK, Permin A, Gjetting T, Andresen TL, Larsen S, Wegener KM, Lykkesfeldt J, Jantzen K. 2015. In vivo toxicity of cationic micelles and liposomes. Nanomedicine: Nanotechnology, Biology and Medicine 11:467-477.",
      "citeRegEx" : "Immordino et al\\.,? 2006",
      "shortCiteRegEx" : "Immordino et al\\.",
      "year" : 2006
    }, {
      "title" : "An intracellular lamellar–nonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents",
      "author" : [ "R Koynova", "L Wang", "RC. MacDonald" ],
      "venue" : "Proceedings of the National Academy of Sciences 103:14373-14378. Lee SM, Kim JS, Oh YK, Lee YB, Sah H. 2005. Biodistribution and genotoxicity of transferrin-conjugated liposomes/DNA complexes in mice. Macromolecular Research 13:218-222.",
      "citeRegEx" : "Koynova et al\\.,? 2006",
      "shortCiteRegEx" : "Koynova et al\\.",
      "year" : 2006
    }, {
      "title" : "The influence of the structural orientation of amide linkers on the serum compatibility and lung transfection properties of cationic amphiphiles",
      "author" : [ "S Marepally", "V Chandrashekhar", "RC Reddy", "R Prabhakar", "S Bojja", "A. Chaudhuri" ],
      "venue" : "Meka RR, Godeshala S, Marepally S, Thorat K, K. RRH, Dhayani A, Hiwale A, Banerjee R, Chaudhuri A, Vemula PK. 2016. Asymmetric cationic lipid based non-viral vectors for an efficient nucleic acid delivery.",
      "citeRegEx" : "Marepally et al\\.,? 2011",
      "shortCiteRegEx" : "Marepally et al\\.",
      "year" : 2011
    }, {
      "title" : "Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors",
      "author" : [ "SK Mondal", "S Jinka", "K Pal", "S Nelli", "SK Dutta", "E Wang", "A Ahmad", "KM AlKharfy", "D Mukhopadhyay", "R. Banerjee" ],
      "venue" : "RSC Advances",
      "citeRegEx" : "Mondal et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Mondal et al\\.",
      "year" : 2016
    }, {
      "title" : "New Developments in Liposomal Drug Delivery",
      "author" : [ "BS Pattni", "VV Chupin", "VP. Torchilin" ],
      "venue" : "Chemical Reviews 115:10938-10966. Pore SK, et al. 2013. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect. Biomaterials 34:6804-6817. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. 2018. Progress and challenges towards targeted delivery",
      "citeRegEx" : "Pattni et al\\.,? 2015",
      "shortCiteRegEx" : "Pattni et al\\.",
      "year" : 2015
    }, {
      "title" : "A Lipid-Modified Estrogen Derivative that Treats Breast Cancer Independent of Estrogen Receptor Expression through Simultaneous Induction of Autophagy and Apoptosis",
      "author" : [ "S Sinha" ],
      "venue" : "of cancer therapeutics. Nature Communications",
      "citeRegEx" : "Sinha,? \\Q2011\\E",
      "shortCiteRegEx" : "Sinha",
      "year" : 2011
    }, {
      "title" : "Genotoxicity of metal nanoparticles",
      "author" : [ "H Xie", "MM Mason", "JP Wise", "Sr" ],
      "venue" : "vaccine. Cancer Immunol Immunother",
      "citeRegEx" : "Xie et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Xie et al\\.",
      "year" : 2011
    } ],
    "referenceMentions" : [ {
      "referenceID" : 7,
      "context" : ", stearoyldecanoylethylphosphatidyl choline (Koynova et al. 2006).",
      "startOffset" : 44,
      "endOffset" : 65
    }, {
      "referenceID" : 6,
      "context" : "carrying unsaturated and saturated cationic lipids are also used (Immordino et al. 2006).",
      "startOffset" : 65,
      "endOffset" : 88
    }, {
      "referenceID" : 0,
      "context" : "D0-lipid associated, anticancer lipoplex (DXE-lipoplex) was previously tested to act against pancreatic cancer, melanoma and breast cancer stem cells (Ahmad et al. 2016) with no visible toxicological effect.",
      "startOffset" : 150,
      "endOffset" : 169
    } ],
    "year" : 2019,
    "abstractText" : "Cationic lipids are well known excipients for nanometric liposomal gene delivery systems. However, because of the suspected, collateral toxicity in normal cells, the use of cationic lipids for the treatment of human tumor is largely limited. Recently, using a glucocorticoid receptor (GR)-targeted liposomal, anticancer delivery system (DXE nano-lipoplex), which carried cationic lipid of saturated twin aliphatic chains, we accomplished efficient anti-tumor effect in aggressive and drug-resistant tumor models of breast cancer stem cells, melanoma and pancreatic cancer. However, to explore its human clinical use, a complete in vivo genotoxicological profilebased safety assessment was due. In addition, in this study we incorporated another nanolipoplex (D1XE) that carried cationic lipid with one unsaturated aliphatic chain. The study was to compare the genotoxic and anti-tumor profile of both the lipoplexes, which differ by the chemical identity of only one constituent cationic lipid, i.e., lipid either carrying both the saturated aliphatic chains or carrying one saturated and one unsaturated aliphatic chains. It is well-known that unsaturated aliphatic chains in lipid impart efficient cell surface fusogenic property in lipid formulations. Herein, we report that nanoplex with unsaturated cationic lipid (D1XE) exhibited better physical appearance with less flocculent behavior than nanoplex with saturated lipid (DXE). Upon multiple injections, D1XE nanoplex imparted better tumor regression but most importantly, exhibited much lower overall toxicity (e.g., genotoxicity, weight loss etc.) than DXE nanoplex. With higher antitumor effect but lower genotoxic effect, D1XE is proved to be a better nanoplex than DXE for potential clinical trial. Thus, this study clearly delineates the importance of incorporating a constituent lipid that carries single unsaturated aliphatic chain towards developing efficient anti-tumor nano-lipoplexes with reduced genotoxicity.",
    "creator" : null
  }
}